RT Journal Article
SR Electronic
T1 Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.19.21268078
DO 10.1101/2021.12.19.21268078
A1 Suzuki, Yasuhito
A1 Shibata, Yoko
A1 Minemura, Hiroyuki
A1 Nikaido, Takefumi
A1 Tanino, Yoshinori
A1 Fukuhara, Atsuro
A1 Kanno, Ryuzo
A1 Saito, Hiroyuki
A1 Suzuki, Shuzo
A1 Ishii, Taeko
A1 Inokoshi, Yayoi
A1 Sando, Eiichiro
A1 Sakuma, Hirofumi
A1 Kobayashi, Tatsuho
A1 Kume, Hiroaki
A1 Kamimoto, Masahiro
A1 Aoki, Hideko
A1 Takama, Akira
A1 Kamiyama, Takamichi
A1 Nakayama, Masaru
A1 Saito, Kiyoshi
A1 Tanigawa, Koichi
A1 Sato, Masahiko
A1 Kanbe, Toshiyuki
A1 Kanzaki, Norio
A1 Azuma, Teruhisa
A1 Sakamoto, Keiji
A1 Nakamura, Yuichi
A1 Otani, Hiroshi
A1 Waragai, Mitsuru
A1 Maeda, Shinsaku
A1 Ishida, Tokiya
A1 Sugino, Keishi
A1 Tsukada, Yasuhiko
A1 Yamada, Ryuki
A1 Sato, Riko
A1 Omuna, Takumi
A1 Tomita, Hikaru
A1 Saito, Mikako
A1 Watanabe, Natsumi
A1 Rikimaru, Mami
A1 Kawamata, Takaya
A1 Umeda, Takashi
A1 Morimoto, Julia
A1 Togawa, Ryuichi
A1 Sato, Yuki
A1 Saito, Junpei
A1 Kanazawa, Kenya
A1 Iseki, Ken
YR 2021
UL http://medrxiv.org/content/early/2021/12/21/2021.12.19.21268078.abstract
AB Background Mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may reduce the efficacy of neutralizing monoclonal antibody therapy against coronavirus disease 2019 (COVID-19). We here evaluated the efficacy of casirivimab-imdevimab in patients with mild-to-moderate COVID-19 during the Delta variant surge in Fukushima Prefecture, Japan.Methods We enrolled 949 patients with mild-to-moderate COVID-19 who were admitted to hospital between July 24, 2021 and September 30, 2021. Clinical deterioration after admission was compared between casirivimab-imdevimab users (n = 314) and non-users (n = 635).Results The casirivimab-imdevimab users were older (P < 0.0001), had higher body temperature (≥ 38°C) (P < 0.0001) and greater rates of history of cigarette smoking (P = 0.0068), hypertension (P = 0.0004), obesity (P < 0.0001), and dyslipidemia (P < 0.0001) than the non-users. Multivariate logistic regression analysis demonstrated that receiving casirivimab-imdevimab was an independent factor for preventing deterioration (odds ratio 0.448; 95% confidence interval 0.263–0.763; P = 0.0023). Furthermore, in 222 patients who were selected from each group after matching on the propensity score, deterioration was significantly lower among those receiving casirivimab-imdevimab compared to those not receiving casirivimab-imdevimab (7.66% vs 14.0%; p = 0.021).Conclusion This real-world study demonstrates that casirivimab-imdevimab contributes to the prevention of deterioration in COVID-19 patients after hospitalization during a Delta variant surge.Summary This real-world retrospective study demonstrates the contribution of treatment with casirivimab-imdevimab to the prevention of deterioration in patients with mild-to-moderate coronavirus disease 2019 (COVID-19) even during the Delta variant pandemic.Competing Interest StatementYoko Shibata and Hiroyuki Minemura received lecture fees and research grants from Chugai Pharmaceutical Co., Ltd. The other authors report no conflicts of interest related to this study.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The need for informed consent was waived because the study is retrospective. This study was approved by the Ethics Committee of Fukushima Medical University (approval number 2020-118, approved on August 3, 2020, updated September 01, 2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.BMIbody mass indexCIconfidence intervalCKDchronic kidney diseaseCOVID-19coronavirus disease 2019CRPC-reactive proteinECMOextracorporeal membrane oxygenationIQRinterquartile rangeLDHlactate dehydrogenaseORodds ratioPCRpolymerase chain reactionSARS-CoV-2severe acute respiratory syndrome coronavirus 2